Intracochlear Platelet-rich Fibrin Application in Cochlear Implantation
Primary Purpose
Hearing Loss, Sensorineural
Status
Recruiting
Phase
Not Applicable
Locations
Turkey
Study Type
Interventional
Intervention
intracochlear platelet rich fibrin administration
Sponsored by
About this trial
This is an interventional prevention trial for Hearing Loss, Sensorineural focused on measuring cochlear implant, platelet rich fibrin
Eligibility Criteria
Inclusion Criteria:
- Patients with sensorineural hearing loss
- Patients who will have cochlear implant surgery with CI422 electrode
Exclusion Criteria:
- Patients with cochlear abnormality
- Patients with auditory neuropathy
Sites / Locations
- Pamukkale UniversityRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
intracochlear prf administration group
Arm Description
intracochlear prf administration group
Outcomes
Primary Outcome Measures
Electrode Impedance(Ohm)
All intra-operative impedance values will be acquired after surgery. They will be repeated in first week, 1, 3 and 6th months
Secondary Outcome Measures
Electrode thresholds(CL)
All intra-operative threshold values will be acquired after surgery. They will be repeated in first week, 1, 3 and 6th months
Full Information
NCT ID
NCT05215197
First Posted
January 18, 2022
Last Updated
September 14, 2023
Sponsor
Pamukkale University
1. Study Identification
Unique Protocol Identification Number
NCT05215197
Brief Title
Intracochlear Platelet-rich Fibrin Application in Cochlear Implantation
Official Title
Intracochlear Platelet-rich Fibrin Application in Cochlear Implantation
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 31, 2022 (Actual)
Primary Completion Date
December 1, 2024 (Anticipated)
Study Completion Date
December 20, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Pamukkale University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Fibrosis due to surgical trauma is a common problem with cochlear implants. Fibrosis limits the effectiveness of implant and increases the power consumption. Our aim in this study is to benefit from the anti-inflammatory effects of autologous platelet-rich fibrin to reducing the fibrotic cascade.
Detailed Description
The most common problem with cochlear implants is that their effectiveness decreases over time and they are not functional enough mainly due to fibrosis.
Our aim in this study is to benefit from the anti-inflammatory effects of autologous platelet-rich fibrin to reducing the fibrotic cascade.
Cochlear implant application will be performed under general anesthesia. After the postauricular incision and mastoidectomy, posterior tympanotomy will find the middle ear and from there the round window, and platelet fibrin prepared with the i-prf technique will be locally applied to the round window during the operation, and then implantation will be performed.
The points where the electrode enters the cochlea will be covered with fascia.
Intraoperative NRT and impedances will be measured on all electrodes in all patients, and NRT and impedance measurements will be repeated in the 1st week, 1st month, 3rd and 6th months postoperatively.
Custom Sound EP 5.0 (5.0.4.136) program provided by Cochlear company will be used for these measurements.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hearing Loss, Sensorineural
Keywords
cochlear implant, platelet rich fibrin
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
open uncontrolled
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
intracochlear prf administration group
Arm Type
Experimental
Arm Description
intracochlear prf administration group
Intervention Type
Drug
Intervention Name(s)
intracochlear platelet rich fibrin administration
Intervention Description
intracochlear platelet rich fibrin administration during routine cochlear implantation surgery
Primary Outcome Measure Information:
Title
Electrode Impedance(Ohm)
Description
All intra-operative impedance values will be acquired after surgery. They will be repeated in first week, 1, 3 and 6th months
Time Frame
1-6 months
Secondary Outcome Measure Information:
Title
Electrode thresholds(CL)
Description
All intra-operative threshold values will be acquired after surgery. They will be repeated in first week, 1, 3 and 6th months
Time Frame
1-6 months
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients with sensorineural hearing loss
Patients who will have cochlear implant surgery with CI422 electrode
Exclusion Criteria:
Patients with cochlear abnormality
Patients with auditory neuropathy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Fazil N Ardic, MD
Phone
902582965799
Email
fnardic@pau.edu.tr
Facility Information:
Facility Name
Pamukkale University
City
Denizli
ZIP/Postal Code
20070
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fazil N Ardic, MD
Phone
+902582965799
Email
fnardic@pau.edu.tr
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
The metadata will be shared by a public depository.
Learn more about this trial
Intracochlear Platelet-rich Fibrin Application in Cochlear Implantation
We'll reach out to this number within 24 hrs